scholarly journals New Contraception Update — Annovera, Phexxi, Slynd, and Twirla

2022 ◽  
Author(s):  
Courtney C. Baker ◽  
Melissa J. Chen
Keyword(s):  
Contraceptive Method ◽  
Infection Prevention ◽  
Ethinyl Estradiol ◽  
Safety Data ◽  
Pregnancy Prevention ◽  
Hormonal Contraceptive ◽  
Urogenital Infection ◽  
The Usa ◽  
One Year ◽  
Combined Hormonal Contraceptive

Abstract Purpose of Review In this review, we discuss the efficacy, safety, and benefits of four new contraceptive products available in the USA, specifically Annovera, Phexxi, Slynd, and Twirla. Recent Findings Annovera is a vaginal ring releasing ethinyl estradiol and segesterone acetate that can be used for up to one year (13 cycles), offering patients an effective, user-controlled option that may improve contraceptive access for those in low-resource settings or those with barriers to retrieving monthly prescriptions; however, given limited efficacy and safety data in people with body mass index (BMI) > 29 kg/m2, clinicians may consider whether Annovera is an appropriate contraceptive method for obese patients if there are other acceptable alternatives. Phexxi prescription-only vaginal gel is a user-controlled, non-hormonal, on-demand contraceptive method that represents a novel addition to the market with its additional uses as a personal lubricant and as a potential microbicide for urogenital infection prevention. Slynd, a drospirenone-only pill, provides more flexibility for delayed or missed pills while maintaining efficacy and a more favorable bleeding profile compared with previously available progestin-only pills. Lastly, Twirla is a transdermal patch releasing ethinyl estradiol and levonorgestrel that offers users an additional option for a user-controlled, combined hormonal contraceptive method without daily dosing; however, prescription is limited to patients with BMI < 30 kg/m2 due to decreased efficacy and VTE events in people with obesity. Summary The addition of these products expands the available options for pregnancy prevention to address unmet contraceptive needs.

Self-described impact of noncompliance among users of a combined hormonal contraceptive method

Contraception ◽  
2008 ◽  
Vol 77 (4) ◽  
pp. 276-282 ◽  
Author(s):  
Iñaki Lete ◽  
José Luis Doval ◽  
Ezequiel Pérez-Campos ◽  
Roberto Lertxundi ◽  
Marta Correa ◽  
...  
Keyword(s):  
Contraceptive Method ◽  
Hormonal Contraceptive ◽  
Combined Hormonal Contraceptive

scholarly journals Impact of counselling on selecting a hormonal contraceptive method

2018 ◽  
Vol 7 (8) ◽  
pp. 3325
Author(s):  
Darshna M. Patel ◽  
Vandita K. Salat ◽  
Mahesh M. Patel
Keyword(s):  
Family Planning ◽  
Health Care Professionals ◽  
Contraceptive Method ◽  
Unmet Need ◽  
Hormonal Contraceptive ◽  
Maximum Difference ◽  
Contraceptive Methods ◽  
Important Indicator ◽  
Contraceptive Pills ◽  
Combined Hormonal Contraceptive

Background: Unmet need for family planning is an important indicator for assessing the demand for family planning services. As per NFHS-4, the contraceptive prevalence rate in women age 15-49 years was 53.5 % and the unmet need for family planning among married women was 12.9%. Counselling provides the Health care professionals (HCPs) an opportunity to understand the individual need of a contraceptive seeker.Methods: This was a cross-sectional, observational study conducted at GMERS hospital, Valsad during June 2017 to October 2017. Sexually active women of 18 to 40 years who consulted HCPs for contraception and who interested in starting hormonal contraceptive method or expressed interest in switching (changing) to hormonal methods were included in the study. Total 213 women were enrolled in the study.  Questionnaires with information on the women’s pre- and post-counseling contraceptive choice, her perceptions, and the reasons behind her post-counseling decision were filled both by the HCP and the participating women. The completed questionnaires were collected and analyzed.Results: During pre-counseling, most common hormonal contraceptive method selected by women was combined hormonal contraceptive pills followed by DMPA, LNG-IUS and POPs. In present study, structured contraception counseling helped most women (97.2 %) to choose a contraceptive method. There were statistically significant differences in choice of contraceptive methods during pre and post-counseling except COCs. Among hormonal contraceptive methods, maximum difference was observed for choice of the COCs after counseling as compared to pre-counseling. Counseling helped more than 90% of the women who were indecisive to choose any contraceptive method. More than three fourth of them opted for hormonal methods with a maximum selection of COCs. The most common reasons for selecting COCs was ease of use for COC, breast feeding for POP and the most common reasons for not choosing other available contraceptive methods was discussion with partner.Conclusions: The combined hormonal contraceptive pills were reported to be the most commonly used contraceptive method. There were statistically significant differences in choice of contraceptive methods during pre and post-counseling with maximum difference in COCs. Counseling helped most of the women who were indecisive to choose any contraceptive method.

scholarly journals Weight gain and menstrual abnormalities between users of Depo-provera and Noristerat

2019 ◽  
Vol 8 (6) ◽  
pp. 2226
Author(s):  
Yusuf Abisowo Oshodi ◽  
Joy Oyinyechi Agbara ◽  
Olamide O. Ade fashola ◽  
Fatimat Motunrayo Akinlusi ◽  
Haleema Folasade Olalere ◽  
...  
Keyword(s):  
Weight Gain ◽  
Contraceptive Method ◽  
Demographic Data ◽  
Unwanted Pregnancy ◽  
Hormonal Contraceptive ◽  
Other Information ◽  
Menstrual Pattern ◽  
One Year ◽  
Long Acting ◽  
Retrospective Comparative Study

Background: Progesterone only injectable contraceptive provides long acting contraception against unwanted pregnancy. Alterations in menstrual pattern are a well known side effect of this effective contraceptive method. Objective of this study was to compare the weight gain and pattern of menstrual abnormalities in users of Depot Medroxyprogesterone Acetate (DMPA) and Norethisterone Enanthate (Noristerat) in LASUTH.Methods: Retrospective comparative study conducted over a 3year period (January 2013 to December 2015) and involving 237 subjects who used injectable hormonal contraceptive (either DMPA or Noristerat). Case records of all the subjects were retrieved and information obtained on socio-demographic data, parity, previous contraceptive method and reason for discontinuation within one year of usage. Other information including subjects’ weight, menstrual cycle length and pattern, and side effects were collected at 3, 6 and 12 months for DMPA group and 2, 4 and 12 months interval for Noristerat group. Data obtained were analyzed using statistical packages for social sciences (version 19).Results: The combined mean age was 34.15±1.36 years. The mean weight at commencement was 68.16kg for DMPA and 66.61kg for Noristerat users while after a year, it significantly increased to 71.27kg for DMPA and 69.07kg for Noristerat users (P<0.05). No change in menstrual pattern was noted in 10% of DMPA and 7% of Noristerat users while 60% of DMPA and 57% of Noristerat had amenorrhoea by the end one year period. Five percent each of DMPA and Noristerat users perceived weight gain as problem significant enough to discontinue both methods respectively. Overall, 24% of DMPA and 19.1% of Noristerat users discontinued use after one year.Conclusions: There were significant weight gain between users of DMPA and Noristerat which was not considered a problem. Amenorrhoea was the commonest menstrual abnormality responsible for discontinuation of either method.

Factors affecting women's selection of a combined hormonal contraceptive method: the TEAM-06 Spanish cross-sectional study

Contraception ◽  
2007 ◽  
Vol 76 (2) ◽  
pp. 77-83 ◽  
Author(s):  
Iñaki Lete ◽  
Jose Luis Doval ◽  
Ezequiel Pérez-Campos ◽  
Rafael Sánchez-Borrego ◽  
Marta Correa ◽  
...  
Keyword(s):  
Contraceptive Method ◽  
Hormonal Contraceptive ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Factors Affecting ◽  
Selection Of ◽  
Combined Hormonal Contraceptive

Medical contraindications to combined hormonal contraceptive use among women using methods prescribed by a pharmacist

Contraception ◽  
2021 ◽  
Author(s):  
Maria I. Rodriguez ◽  
Menolly Kaufman ◽  
Brynna Manibusan ◽  
Lorinda Anderson ◽  
K. John McConnell
Keyword(s):  
Contraceptive Use ◽  
Hormonal Contraceptive ◽  
Combined Hormonal Contraceptive

scholarly journals Hormonal contraceptive method choice among young, low-income women: How important is the provider?

2010 ◽  
Vol 81 (3) ◽  
pp. 349-354 ◽  
Author(s):  
Cynthia C. Harper ◽  
Beth A. Brown ◽  
Anne Foster-Rosales ◽  
Tina R. Raine
Keyword(s):  
Low Income ◽  
Contraceptive Method ◽  
Hormonal Contraceptive ◽  
Method Choice ◽  
Low Income Women

Estetrol and the possibilities of its clinical use

2021 ◽  
Vol 86 (3) ◽  
pp. 217-221
Author(s):  
Petr Křepelka ◽  
Keyword(s):  
Ethinyl Estradiol ◽  
Fetal Liver ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Cardiovascular Complications ◽  
Estradiol Valerate ◽  
Planned Parenthood ◽  
Menopausal Syndrome ◽  
Contraceptive Effectiveness ◽  
Combined Hormonal Contraception

Summary Combined hormonal contraceptive methods are one of the most commonly used methods of planned parenthood. They show high contraceptive effectiveness, reasonable cycle control and bring several non-contraceptive benefits. A limitation of the widespread use of combined hormonal contraception is the risk of cardiovascular complications in individuals with specific risk factors. The risk of cardiovascular complications is related to the used estrogen component. Currently, the most common use of estrogen in combined hormonal contraception is ethinyl estradiol and estradiol valerate. The good estrogenic part of combined oral contraceptives is estetrol, a hormone produced exclusively by the fetal liver. Estetrol exhibits a tissue-selective receptor activity. Unlike previously used estrogens, it does not negatively affect the production of liver proteins and blood clotting parameters. Estetrol is not a perspective for combined hormonal contraception only. It is also promising for treating and preventing osteoporosis, hormonal therapy of menopausal syndrome, and vulvovaginal atrophy syndrome.

scholarly journals Superior Mesenteric Vein Thrombosis Associated with Hormonal Contraceptive Use

2016 ◽  
Vol 10 (2) ◽  
pp. 264-268 ◽  
Author(s):  
Nobuatsu Koyama
Keyword(s):  
Superior Mesenteric Vein ◽  
Ethinyl Estradiol ◽  
Lower Abdominal Pain ◽  
Hormonal Contraceptive ◽  
Laboratory Evaluation ◽  
Mesenteric Vein Thrombosis ◽  
Mesenteric Vein ◽  
Vein Thrombosis ◽  
Superior Mesenteric Vein Thrombosis ◽  
History Of

A 44-year-old woman was admitted with a 7-day history of lower abdominal pain and nausea. Physical examination demonstrated tenderness in the lower abdomen without signs of peritonitis. There were no specific findings in the laboratory evaluation. She had a history of dysmenorrhea for 15 years and was taking a combined hormonal contraceptive containing 0.02 mg ethinyl estradiol and 3 mg drospirenone for 19 months. Contrast-enhanced computed tomography showed superior mesenteric vein thrombosis (SMVT). Systemic anticoagulant infusion was immediately administered and the symptoms disappeared within 2 days. The thrombus disappeared after 3 months. This case report suggests that early diagnosis of SMVT and immediate systemic anticoagulant therapy may reduce the rate of intestinal infarction.

scholarly journals Trends in One-Year Recurrent Ischemic Stroke among the Elderly in the USA: 1994–2002

2010 ◽  
Vol 30 (5) ◽  
pp. 525-532 ◽  
Author(s):  
Norrina B. Allen ◽  
Theodore R. Holford ◽  
Michael B. Bracken ◽  
Larry B. Goldstein ◽  
George Howard ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
The Elderly ◽  
The Usa ◽  
One Year

Solving SARA Compliance with Computerized Hazardous Materials Tracking

1992 ◽  
Vol 8 (01) ◽  
pp. 23-27
Author(s):  
Don Johnston ◽  
Dave Schoenleber
Keyword(s):  
Safety Data ◽  
Hazardous Materials ◽  
Materials Management ◽  
Material Management ◽  
Chemical Release ◽  
Reporting Requirements ◽  
Title Iii ◽  
Toxic Chemical Release ◽  
One Year ◽  
Computerized System

The advent of the Superfund Amendment and Reauthorization Act (SARA) Title III, or the Emergency Planning and Citizen Right-to-Know Act (EPCRA) has forced facilities to keep track of hazardous materials as never before. EPCRA contains five major reporting requirements, including planning notification, emergency release notification, Material Safety Data Sheet (MSDS) submission, chemical inventory reporting, and toxic chemical release reporting. The complexity and vastness of these requirements all but require a computerized system for hazardous material management. Peterson Builders, Inc., developed a computerized hazardous materials management system capable of meeting the requirements of EPCRA. After one year of operation, the system has proven successful. This paper discusses Peterson Builders' experience in implementing the system, system design, and future considerations for the system.

Sign in / Sign up

Export Citation Format

Share Document